Gilead Sciences Inc. [NASDAQ: GILD] loss -1.19% or -0.85 points to close at $70.88 with a heavy trading volume of 9710245 shares. The company report on July 30, 2020 that Gilead Sciences Announces Third Quarter 2020 Dividend.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the third quarter of 2020. The dividend is payable on September 29, 2020, to stockholders of record at the close of business on September 15, 2020. Future dividends will be subject to Board approval.
About Gilead Sciences.
It opened the trading session at $72.02, the shares rose to $72.31 and dropped to $70.475, the range by which the price of stock traded the whole day. The daily chart for GILD points out that the company has recorded 5.16% gains over the past six months. However, it is still -16.41% lower than its most recent low trading price.
If we look at the average trading volume of 10.21M shares, GILD reached to a volume of 9710245 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Gilead Sciences Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $81.21 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on July 31, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price from $73 to $74. The new note on the price target was released on July 31, 2020, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another drop from $89 to $87, while RBC Capital Mkts kept a Outperform rating on GILD stock. On July 31, 2020, analysts decreased their price target for GILD shares from 90 to 85.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.84, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 4.17. The Price to Book ratio for the last quarter was 4.05, with the Price to Cash per share for the same quarter was set at 15.93. Price to Free Cash Flow for GILD in the course of the last twelve months was 18.15 with Quick ratio for the last quarter at 2.90.
Trading performance analysis for GILD stock
Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.87. With this latest performance, GILD shares dropped by -7.66% in over the last four-week period, additionally plugging by 5.16% over the last 6 months – not to mention a rise of 11.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 36.68, with the RSI for the last a single of trading hit 34.34, and the three-weeks RSI is set at 40.69 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 75.22, while it was recorded at 71.50 for the last single week of trading, and 71.30 for the last 200 days.
Gilead Sciences Inc. [GILD]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +22.22 and a Gross Margin at +79.06. Gilead Sciences Inc.’s Net Margin is presently recorded at +24.13.
Return on Total Capital for GILD is now 10.25, given the latest momentum, and Return on Invested Capital for the company is 11.81. Return on Equity for this stock inclined to 24.53, with Return on Assets sitting at 8.60. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 112.40. Additionally, GILD Total Debt to Total Capital is recorded at 52.92, with Total Debt to Total Assets ending up at 41.08. Long-Term Debt to Equity for the company is recorded at 100.87, with the Long-Term Debt to Total Capital now at 47.49.
Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $456,441 per employee. Receivables Turnover for the company is 6.46 with a Total Asset Turnover recorded at a value of 0.36.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.00.
Gilead Sciences Inc. [GILD]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.75/share EPS, while the average EPS was predicted by analysts to be reported at 1.74/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 1.92%.
An analysis of insider ownership at Gilead Sciences Inc. [GILD]
There are presently around $71,617 million, or 82.30% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: VANGUARD GROUP INC with ownership of 107,093,415, which is approximately 3.201% of the company’s market cap and around 0.41% of the total institutional ownership; BLACKROCK INC., holding 101,214,991 shares of the stock with an approximate value of $7.17 billion in GILD stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $6.8 billion in GILD stock with ownership of nearly 12.744% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 826 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 133,366,387 shares. Additionally, 812 investors decreased positions by around 137,983,735 shares, while 153 investors held positions by with 739,052,127 shares. The mentioned changes placed institutional holdings at 1,010,402,249 shares, according to the latest SEC report filing. GILD stock had 200 new institutional investments in for a total of 9,352,071 shares, while 156 institutional investors sold positions of 22,741,682 shares during the same period.